Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. Tamoxifen là chất đối kháng receptor của receptor estrogen tại mô ngực thông qua chất chuyển hóa có hoạt tính, hydroxytamoxifen. ở một số mô khác như nội mạc tử cung tamoxifen đóng vai trò chất chủ vận, do đó Tamoxifen đóng vai trò giữa chất chủ vận và chất đối kháng chủ vận. Tamoxifen thường được sử dụng cho liệu pháp nội tiết (kháng-estrogen) trong điều trị ung thư vú ở phụ nữ mãn kinh, và đây cũng là chuẩn điều trị cho phụ nữ mãn kinh mặc dù nhómức chế aromatase cũng thường xuyên được sử dụng.
Tamoxifen won't work on hormone-receptor-negative breast cancer. Tamoxifen is available in two forms: a pill taken once a day (brand name: Nolvadex) or a liquid form (brand name: Soltamox). If you dislike pills or you're having trouble swallowing tamoxifen pills, Soltamox can help make it easier to stay on your treatment plan. Most doctors recommend taking tamoxifen at the same time each day. — while you are taking tamoxifen and for 2 months afterward. You should not take tamoxifen if you are breastfeeding, pregnant, trying to get pregnant, or if there is any chance that you could be pregnant. You should use an effective non-hormonal type of birth control — such as condoms, a diaphragm along with spermicide, or a non-hormonal I. Ask your doctor which type of non-hormonal birth control would be best for you. Since its approval in 1998, tamoxifen has been used to treat millions of women and men diagnosed with hormone-receptor-positive breast cancer. While an aromatase inhibitor is the first hormonal therapy medicine choice for postmenopausal women, tamoxifen is the first choice for premenopausal women and is still a good choice for postmenopausal women who can't take an aromatase inhibitor. Tamoxifen is a SERM (selective estrogen receptor modifier). It acts as an estrogen receptor (ER) antagonist in some tissue (in this case, breasts) and an ER agonist in other tissue (in this case, bone and uterus). It is often used for breast cancer treatment for this reason, as it prevents osteoporosis and the spread of estrogen-sensitive cancer in the breasts and can be combined with Gn RH blockers (either Gn RH antagonists or agonists) for treatment. In other words, tamoxifen acts as an anti estrogen in the breasts but as estrogen in bones and skin. This medication would likely be effective in halting breast growth (as it would prevent estrogen from acting in the breasts), and is already used for the treatment of fibrocystic breasts and breast cancer due to lack of side effects compared to other medications like danazol. It can possibly lower levels of IGF-1 (insulin growth factor 1), but also can lead to higher levels of estrogen in the uterus, which could lead to uterine cancer (though the risks are small). Unlike tamoxifen, raloxifene is an ER antagonist in uterine tissue (lowering the risk for uterine cancer), and has a greater ER affinity in bone. Tamoxifen has been proven to lower fibroglandular and breast volume/density in premenopausal women, and it and other SERMS have been proven to move fat distribution from the butt and central region to the legs.
Raloxifene, developed by Eli Lilly in 1997 and sold under the brand name Evista among others, is a medication which is used in the prevention and treatment of osteoporosis in postmenopausal women and to reduce the risk of breast cancer in postmenopausal women with osteoporosis or at high risk for breast cancer. Raloxifene is a teratogen; i.e., it can cause developmental abnormalities such as birth defects. Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, and vision changes. Black box warnings were added to the label of raloxifene in 2007 warning of increased risk of death due to stroke for postmenopausal women with documented coronary heart disease or at increased risk for major coronary events, as well as increased risk for deep vein thrombosis and pulmonary embolism. A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen and raloxifene, used to treat breast cancer, significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects. A recent human case report in July 2016 suggests that raloxifene may in fact, at some point, also stimulate breast cancer growth leading to a reduction of advanced breast cancer disease upon the withdrawal of the drug. Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! It has been the standard endocrine (anti-estrogen) therapy for hormone-positive early breast cancer, although aromatase inhibitors have been proposed for postmenopausal women. Estrogen binds to and activates the estrogen receptor in these cells. Categories: Selective estrogen receptor modulators | Chemopreventive agents | Astra Zeneca | Cancer treatments | IARC Group 1 carcinogens | Treatment of bipolar disorder | Alkenes | Stilbenoids | Phenol ethers Tamoxifen is an antagonist of the estrogen receptor in breast tissue. Tamoxifen is metabolized into compounds that also bind to the estrogen receptor but do not activate it. Furthermore tamoxifen prevents estrogen from binding to its receptor. Tamoxifen was discovered by ICI Pharmaceuticals (now Astra Zeneca) and is sold under the trade names Nolvadex, Istubal, and Valodex. However, the drug, even before its patent expiration, was and still is widely referred to by its generic name "tamoxifen." In 2006, the large STAR clinical study concluded that raloxifene is equally effective in reducing the incidence of breast cancer, but after an average 4-year follow-up there were 36% fewer uterine cancers and 29% fewer blood clots in women taking raloxifene than in women taking tamoxifen, although the difference is not statistically significant. In 2005, the ATAC trial showed that after average 68 months following a 5 year adjuvant treatment, the group that received anastrozole (Arimidex) had significantly better results than the tamoxifen group in measures like disease free survival, but no overall mortality benefit. In men, tamoxifen "nolvaldex" is sometimes used by steroid-taking, weight-training athletes.
Tamoxifen acts as an anti-estrogen inhibiting agent in the mammary tissue, but as an. Nolvadex-D Tab 20mg, Tablet, 20 mg, Oral, Astra Zeneca, 1995-12-31. Drug Page; Wikipedia Tamoxifen. Side Effects. Drug information provided by IBM Micromedex Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.